1. Centers for Medicare & Medicaid Services. Interim report on the CMS national partnership to improve dementia care in nursing homes: Q4 2011 Q1 2014. 11 Apr 2014. https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Policy-and-Memos-to-States-and-Regions-Items/Survey-and-Cert-Letter-14-19
2. DeArment A. Otsuka/Lundbeck’s Rexulti has time to build a lead in the Alzheimer’s agitation market. Scrip 2023 May 11. https://scrip.pharmaintelligence.informa.com/SC148364/OtsukaLundbecks-Rexulti-Has-Time-To-Build-A-Lead-In-The-Alzheimers-Agitation-Market
3. Food and Drug Administration. April 14, 2023: Joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Peripheral and Central Nervous System Drugs Advisory Committee meeting announcement. 14 Apr 2023. https://www.fda.gov/advisory-committees/advisory-committee-calendar/april-14-2023-joint-meeting-psychopharmacologic-drugs-advisory-committee-and-peripheral-and-central
4. Food and Drug Administration. Meeting transcript: Joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Peripheral and Central Nervous System Drugs Advisory Committee. 14 Apr 2023. https://www.fda.gov/media/169116/download
5. Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria